EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis

Nobuharu Tamaki iD, Daniel Q Huang, Hyung Woong Lee, Soo Young Park iD, Yu Rim Lee iD, Dong Hyun Sinn iD, Tae Seop Lim, Hiroyuki Marusawa, Seng Gee Lim iD, Hironori Ochi iD, Masahiko Kondo, Yasushi Uchida und 4 weitere

Journal of Gastroenterology and Hepatology · 2025

DOI: 10.1111/jgh.16986 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Nobuharu Tamaki und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Digital Healthcare Research Grant through the Seokchun Caritas Foundation, Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Among patients with hepatitis B virus (HBV)‐infected compensated cirrhosis and low‐level viremia, there are limited data for comparative outcomes between those treated with oral nucleos(t)ide analogs versus those not. We conducted a large, multi‐ethnic, multi‐center study to examine the impact of antiviral treatment (AVT) on long‐term hepatocellular carcinoma (HCC) risk for compensated cirrhosis and low‐level viremia.

Methods

Patients with compensated cirrhosis and low‐level viremia (serum HBV‐DNA 20–2000 IU/mL) at baseline or before AVT were screened for eligibility from 19 hospitals in South Korea, Singapore, and Japan. The primary outcome was HCC development, compared between those receiving AVT versus those untreated throughout follow‐up.

Results

Among 848 patients (mean age 55.7 years and 66.9% male), AVT ( n = 233) was associated with significantly lower annual HCC incidence compared to non‐AVT ( n = 615); 1.72/100 versus 2.99/100 person‐years (PY), respectively ( p = 0.033). Multivariable Cox‐regression analyses determined that AVT was associated with significantly lower HCC risk, compared to non‐AVT (adjusted HR [HR] 0.514, 95% confidence interval [CI] 0.271–0.976; p = 0.042). In a landmark analysis, HCC incidence was similar between two groups until 18 months, but after this landmark, the treated group had the significantly lower HCC risk compared to untreated group ( p = 0.012). Furthermore, propensity score‐matching analysis consistently showed that AVT was associated with significantly lower HCC risk, compared to non‐AVT; the annual HCC incidence of 1.45/100 PYs versus 2.73/100 PY, respectively ( p = 0.043).

Conclusions

Patients with compensated cirrhosis and low‐level viremia may benefit from long‐term AVT, highlighting appropriate amendment of reimbursement guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAntiviral AgentsLiver NeoplasmsLiver CirrhosisViremiaHepatitis B, ChronicHumansMaleFemaleMiddle AgedTime FactorsIncidenceAgedDNA, ViralJapanRepublic of KoreaHepatitis B virusAdultRisk FactorsFollow-Up Studies

Stichwörter der Autor:innen

antiviral treatmentcompensated cirrhosishepatitis B virushepatocellular carcinomalow‐level viremia

Substanzen

Antiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, National University Hospital, Singapore.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Nobuharu Tamaki, Soo Young Park, Yu Rim Lee, Dong Hyun Sinn, Seng Gee Lim, Hironori Ochi, Beom Kyung Kim

Förderung

  • Digital Healthcare Research Grant through the Seokchun Caritas Foundation
  • Japan Agency for Medical Research and Development
  • Ministry of Health, Labour and Welfare of Japan

Zitieren

APA

Tamaki, N., Huang, D. Q., Lee, H. W., Park, S. Y., Lee, Y. R., Sinn, D. H., Lim, T. S., Marusawa, H., Lim, S. G., Ochi, H., Kondo, M., Uchida, Y., Kobashi, H., Furuta, K., Kurosaki, M., & Kim, B. K. (2025). Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16986

Vancouver

Tamaki N, Huang DQ, Lee HW, Park SY, Lee YR, Sinn DH, et al. Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16986

BibTeX
@article{Tamaki2025,
  author = {Tamaki, Nobuharu and Huang, Daniel Q and Lee, Hyung Woong and Park, Soo Young and Lee, Yu Rim and Sinn, Dong Hyun and Lim, Tae Seop and Marusawa, Hiroyuki and Lim, Seng Gee and Ochi, Hironori and Kondo, Masahiko and Uchida, Yasushi and Kobashi, Haruhiko and Furuta, Koichiro and Kurosaki, Masayuki and Kim, Beom Kyung},
  title = {Head‐to‐Head Comparison of Long‐Term HCC Risk of Antivirals‐Treated Versus Untreated Low‐Level Viremia in HBV‐Compensated Cirrhosis},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1111/jgh.16986}
}
Kostenlos starten →